Kymera Therapeutics (KYMR) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $9.10B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Nello Mainolfi |
| IPO Date | 2020-08-21 | CAGR | — |
| Employees | 253 | Website | www.kymeratx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $10.61B | P/E | -31.32 | Forward P/E | -25.39 | PEG | — |
| P/S | 228766.95 | P/B | 9081.54 | P/CF | -57533.44 | P/FCF | -48263.52 |
| Sales | $51.47M | Sales 1Y | -12.6% | Sales 3Y | 10.27% | Sales 5Y | 4.37% |
| EPS | $-3.53 | EPS 1Y | — | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | 1101.57% | EPS QoQ | -27.55% | Sales QoQ Avg | 245.26% | EPS QoQ Avg | -2.12% |
| Gross Margin | 100% | Operating Margin | -697.81% | Profit Margin | -612.17% | ROCE | -22.36% |
| ROA | -19% | ROE | -25% | Altman Z Score | 40.83 | Piotroski Score | 2 |
| Current Ratio | 10.81 | Quick Ratio | 10.81 | Cash Ratio | 2.3 | Op. CF Ratio | -1.42 |
| Debt/Equity | 0.05 | Debt/Assets | 0.05 | Lt Debt/Equity | 0.04 | Lt Debt/Cap. | — |
| Intrst Cov. | -1508.94 | Inventory Turnover | — | Asset Turnover | 0.03 | Receivables Turnover | — |
| Enterprise Value | $10.61B | P/E Ratio | -31.32 |
| Forward P/E | -25.39 | PEG Ratio | — |
| P/S Ratio | 228766.95 | P/B Ratio | 9081.54 |
| P/CF Ratio | -57533.44 | P/FCF Ratio | -48263.52 |
| EPS | $-3.53 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -12.6% | Gross Margin | 1% |
| Operating Margin | -6.98% | Profit Margin | -6.12% |
| ROE | -0.25% | ROA | -0.19% |
| ROCE | -0.22% | Current Ratio | 10.81 |
| Quick Ratio | 10.81 | Cash Ratio | 2.3 |
| Debt/Equity | 0.05 | Interest Coverage | -1508.94 |
| Altman Z Score | 40.83 | Piotroski Score | 2 |
Kymera Therapeutics (KYMR) valuation & financials
Kymera Therapeutics (KYMR) has a market capitalization of $9.10B and trades at a price-to-earnings ratio of -31.3. It operates in the Healthcare sector (Biotechnology).
Kymera Therapeutics's revenue grew -12.6% over the last year.
Kymera Therapeutics's next earnings report is scheduled for August 10, 2026 before market open; analysts estimate EPS of $-0.72.
Kymera Therapeutics (KYMR) — frequently asked questions
When does Kymera Therapeutics (KYMR) report earnings next?
Kymera Therapeutics is expected to report earnings on August 10, 2026 before market open. Analysts estimate EPS of $-0.72.
What is Kymera Therapeutics's market cap?
Kymera Therapeutics (KYMR) has a market capitalization of $9.10B.
What is KYMR's P/E ratio?
Kymera Therapeutics trades at a price-to-earnings ratio of -31.3, with trailing twelve-month EPS of $-3.53.
How fast is Kymera Therapeutics growing?
Kymera Therapeutics's revenue grew -12.6% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)